Jonathan J. Mazelsky's most recent trade in Idexx Laboratories, Inc. was a trade of 23,326 Common Stock done at an average price of $141.6 . Disclosure was reported to the exchange on Feb. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 26 Feb 2026 | 23,326 | 106,932 (0%) | 0% | 141.6 | 3,302,962 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 23,326 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 658.92 per share. | 26 Feb 2026 | 3,660 | 91,254 (0%) | 0% | 658.9 | 2,411,635 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 657.84 per share. | 26 Feb 2026 | 2,860 | 94,914 (0%) | 0% | 657.8 | 1,881,433 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 659.75 per share. | 26 Feb 2026 | 2,859 | 88,395 (0%) | 0% | 659.7 | 1,886,224 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 663.04 per share. | 26 Feb 2026 | 2,589 | 83,606 (0%) | 0% | 663.0 | 1,716,621 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 652.49 per share. | 26 Feb 2026 | 1,669 | 102,887 (0%) | 0% | 652.5 | 1,089,013 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 655.85 per share. | 26 Feb 2026 | 1,488 | 99,117 (0%) | 0% | 655.9 | 975,905 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 656.85 per share. | 26 Feb 2026 | 1,343 | 97,774 (0%) | 0% | 656.8 | 882,143 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 650.67 per share. | 26 Feb 2026 | 1,281 | 105,651 (0%) | 0% | 650.7 | 833,508 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 661.10 per share. | 26 Feb 2026 | 1,200 | 87,195 (0%) | 0% | 661.1 | 793,317 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 653.68 per share. | 26 Feb 2026 | 1,171 | 101,716 (0%) | 0% | 653.7 | 765,455 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 654.63 per share. | 26 Feb 2026 | 1,111 | 100,605 (0%) | 0% | 654.6 | 727,293 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 651.49 per share. | 26 Feb 2026 | 1,095 | 104,556 (0%) | 0% | 651.5 | 713,378 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 662.16 per share. | 26 Feb 2026 | 1,000 | 86,195 (0%) | 0% | 662.2 | 662,157 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 197 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 505.53 per share. | 26 Feb 2026 | 197 | 83,803 (0%) | 0% | 505.5 | 99,589 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 13,407 | 13,407 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 1,099 | 84,521 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 1,099 | 1,099 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 958 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 958 | 83,422 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 629.35 per share. | 12 Feb 2026 | 915 | 83,606 (0%) | 0% | 629.3 | 575,855 | Common Stock |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 395 | 28,846 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 153 | 14,535 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | J. Jonathan Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 2,637 | 14,381 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2025 | 359 | 28,451 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2025 | 123 | 11,743 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 2,386 | 11,620 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Aug 2025 | 1,051 | 82,443 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 598.49 per share. | 08 Aug 2025 | 183 | 83,494 (0%) | 0% | 598.5 | 109,523 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 183 | 0 | - | - | Premium Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 29,260 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 06 Aug 2025 | 29,260 | 112,571 (0%) | 0% | 67.9 | 1,985,291 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 631.61 per share. | 06 Aug 2025 | 7,299 | 93,199 (0%) | 0% | 631.6 | 4,610,096 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 630.59 per share. | 06 Aug 2025 | 6,056 | 100,498 (0%) | 0% | 630.6 | 3,818,874 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 635.13 per share. | 06 Aug 2025 | 3,526 | 86,673 (0%) | 0% | 635.1 | 2,239,457 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 629.82 per share. | 06 Aug 2025 | 3,397 | 106,554 (0%) | 0% | 629.8 | 2,139,508 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 632.56 per share. | 06 Aug 2025 | 3,000 | 90,199 (0%) | 0% | 632.6 | 1,897,689 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 636.15 per share. | 06 Aug 2025 | 1,822 | 84,851 (0%) | 0% | 636.2 | 1,159,068 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 628.27 per share. | 06 Aug 2025 | 1,525 | 109,951 (0%) | 0% | 628.3 | 958,115 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 626.90 per share. | 06 Aug 2025 | 1,095 | 111,476 (0%) | 0% | 626.9 | 686,458 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 636.81 per share. | 06 Aug 2025 | 880 | 83,971 (0%) | 0% | 636.8 | 560,391 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 639.37 per share. | 06 Aug 2025 | 660 | 83,311 (0%) | 0% | 639.4 | 421,985 | Common Stock |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 279 | 28,091 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 75 | 9,234 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 1,561 | 9,159 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 13,880 | 27,812 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2025 | 147 | 13,932 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2025 | 74 | 7,597 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 1,687 | 7,522 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 25,932 | 25,932 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 1,222 | 83,282 (0%) | 0% | 444.5 | 543,216 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,100 | 2,198 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,100 | 84,504 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 958 | 83,404 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 958 | 958 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 689 | 82,446 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 689 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 115 | 13,784 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 38 | 5,835 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2024 | 1,340 | 5,797 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 80 | 13,669 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 22 | 4,456 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 935 | 4,433 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 384 | 81,902 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 384 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 455.08 per share. | 05 Aug 2024 | 170 | 81,732 (0%) | 0% | 455.1 | 77,364 | Common Stock |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 86 | 13,588 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 21 | 3,497 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 994 | 3,476 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 7,994 | 13,502 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2024 | 26 | 5,508 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2024 | 12 | 2,481 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | J. Mazelsky Jonathan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 761 | 2,469 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 550 | 81,496 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2024 | 483 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 21 Feb 2024 | 483 | 82,046 (0%) | 0% | 206.9 | 99,952 | Common Stock |
| Idexx Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 21,335 | 21,335 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 1,839 | 81,563 (0%) | 0% | 560.6 | 1,030,870 | Common Stock |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 1,100 | 83,402 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 1,100 | 3,298 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 974 | 80,655 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | J. Jonathan Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 974 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | J. Jonathan Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 958 | 1,916 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | J. Mazelsky Jonathan | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 958 | 82,302 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 689 | 81,344 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 689 | 689 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 435 | 79,681 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 435 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 12,000 | 29,260 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 07 Feb 2024 | 12,000 | 91,246 (0%) | 0% | 67.9 | 814,200 | Common Stock |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 571.71 per share. | 07 Feb 2024 | 5,356 | 85,890 (0%) | 0% | 571.7 | 3,062,061 | Common Stock |
| Idexx Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 572.53 per share. | 07 Feb 2024 | 4,124 | 81,766 (0%) | 0% | 572.5 | 2,361,094 | Common Stock |
| Idexx Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 574.75 per share. | 07 Feb 2024 | 1,353 | 79,951 (0%) | 0% | 574.8 | 777,639 | Common Stock |
| Idexx Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 575.48 per share. | 07 Feb 2024 | 705 | 79,246 (0%) | 0% | 575.5 | 405,711 | Common Stock |
| Idexx Laboratories | J. Mazelsky Jonathan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 573.19 per share. | 07 Feb 2024 | 462 | 81,304 (0%) | 0% | 573.2 | 264,814 | Common Stock |
| DENTSPLY Sirona Inc | J. Mazelsky Jonathan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 21 | 5,481 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | J. Jonathan Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 6 | 1,707 | - | - | Phantom Stock (Directors Deferred Compensation) DDC |